Roivant Sciences Ltd. (ROIV)

11.21 +0.31 (+2.84%) 收市：04:00PM EDT

Roivant Sciences Ltd.

50 Broadway
7th Floor
London SW1H 0DB
United Kingdom
44 20 7400 3347
https://roivant.com

版塊: Healthcare
行業: Biotechnology
全職員工: 904

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Matthew Gline	CEO & Director	1.77M	無	1984
Dr. Eric Venker M.D., Pharm.D.	President & COO	1.28M	無	1987
Dr. Mayukh Sukhatme M.D.	President, Chief Investment Officer & Director	1.72M	無	1976
Mr. Richard Pulik	Chief Financial Officer	無	無	1979
Ms. Rakhi Kumar	Chief Accounting Officer	無	無	1980
Dr. Huafeng Xu Ph.D.	Chief Technology Officer	無	無	無
Mr. Jo Chen	General Counsel	無	無	無
Ms. Kelly Graff	Head of People	無	無	無
Ms. Marianne L. Romeo	Head of Global Transactions & Risk Management	無	無	1968
Mr. Alex Gasner	Executive Vice President of Roivant Health	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

公司管治

截至 2024年4月29日 止，Roivant Sciences Ltd. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：7；董事會：7；股東權利：3；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。